Subscribe
2020-04-02
Pavel Kapysh / Shutterstock.com
4 September 2020Big PharmaMuireann Bolger

Amarin vows to challenge Vascepa patent ruling

Amarin has announced it will seek an en banc rehearing of a decision at the US Court of Appeals for the Federal Circuit that failed to revive its patents on heart medicine Vascepa (icosapent ethyl).

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Big Pharma
Amarin petitions Supreme Court to revive Vascepa patents
18 February 2021   Irish pharmaceutical company Amarin has petitioned the Supreme Court to revive its patents on its heart medication Vascepa.
Americas
Ruling opens door for Noven’s oestrogen patch generics
10 September 2020   In a victory for pharmaceutical company Amneal, a Delaware court has invalidated claims of three patents covering Noven Pharmaceuticals’ Minivelle oestrogen product.
Americas
FDA approves Dr Reddy’s Vascepa generic
13 August 2020   Indian drugmaker Dr Reddy’s has won approval to launch just the second generic version of heart drug Vascepa, in another blow for Amarin.


Editor's picks

In-house with Bayer: ‘Focus on quality early and stay close to inventors’
Europe
In-house with Bayer: ‘Focus on quality early and stay close to inventors’
15 July 2025

Editor's picks

Europe
In-house with Bayer: ‘Focus on quality early and stay close to inventors’
15 July 2025
Europe
UKIPO rejects Boehringer’s SPC for horse inhaler
8 July 2025
Europe
‘We created law’: G1/24 and the creation of the ‘diamond standard’
3 July 2025
Americas
Bankruptcy judge approves $305m sale of genetics testing company
1 July 2025
Americas
A step too far? Why Stewart’s approach is dividing opinion
24 June 2025
Europe
Diverging in the detail: UPC local divisions and Court of Appeal take different paths
19 June 2025

More on this story

Big Pharma
Amarin petitions Supreme Court to revive Vascepa patents
18 February 2021   Irish pharmaceutical company Amarin has petitioned the Supreme Court to revive its patents on its heart medication Vascepa.
Americas
Ruling opens door for Noven’s oestrogen patch generics
10 September 2020   In a victory for pharmaceutical company Amneal, a Delaware court has invalidated claims of three patents covering Noven Pharmaceuticals’ Minivelle oestrogen product.
Americas
FDA approves Dr Reddy’s Vascepa generic
13 August 2020   Indian drugmaker Dr Reddy’s has won approval to launch just the second generic version of heart drug Vascepa, in another blow for Amarin.

More on this story

Big Pharma
Amarin petitions Supreme Court to revive Vascepa patents
18 February 2021   Irish pharmaceutical company Amarin has petitioned the Supreme Court to revive its patents on its heart medication Vascepa.
Americas
Ruling opens door for Noven’s oestrogen patch generics
10 September 2020   In a victory for pharmaceutical company Amneal, a Delaware court has invalidated claims of three patents covering Noven Pharmaceuticals’ Minivelle oestrogen product.
Americas
FDA approves Dr Reddy’s Vascepa generic
13 August 2020   Indian drugmaker Dr Reddy’s has won approval to launch just the second generic version of heart drug Vascepa, in another blow for Amarin.

More features

AbbVie blocks Humira antitrust suit
WATCH: Enabling success—mastering s112 in the new era of life sciences patents
AstraZeneca suffers defeat over $7bn diabetes patent
US firm Brownstein nabs five from Crowell ‘at pivotal moment’
American Regent secures rare PI win in Hatch-Waxman dispute
WATCH: Patents s101—how to overcome the current complexity of patent eligibility in the US
In-house with Bayer: ‘Focus on quality early and stay close to inventors’
J&J sues over schizophrenia drug generic following patent victory